Efficacy and safety of long‐term treatment with cyclosporin A for atopic dermatitis

Hijnen, DirkJan; Berge, Onno ten; Mik, L. Timmer-de; Bruijnzeel-Koomen, Carla A.F.M.; Bruin‐Weller, Marjolein S. de

doi:10.1111/j.1468-3083.2006.01877.x

Cited by 80 publications

(77 citation statements)

References 16 publications

(27 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These results suggest there is a relationship between long-term CsA treatment and a prolonged remission period for AD. Overall, the adverse events in this study were relatively milder and smaller in number than those in other studies by Hijnen et al 6 and Garcia-Bustinduy et al 13 . In the report of Hijnen et al 6 , the initially used doses of CsA varied up to 5 mg/kg.…”

Section: Discussioncontrasting

confidence: 51%

“…Overall, the adverse events in this study were relatively milder and smaller in number than those in other studies by Hijnen et al 6 and Garcia-Bustinduy et al 13 . In the report of Hijnen et al 6 , the initially used doses of CsA varied up to 5 mg/kg. An increased serum creatinine level more than 30% above the baseline value was observed in 7 patients (9.6 %).…”

Section: Discussioncontrasting

confidence: 51%

“…The remission period seems to be prolonged after the long-term period of CsA treatment for AD. In the report by Hijnen et al 6 , the remission periods in 55% of the patients who underwent CsA treatment for more than 6 months were at least 3 months. These results suggest there is a relationship between long-term CsA treatment and a prolonged remission period for AD.…”

Section: Discussionmentioning

confidence: 99%

“…As the use of CsA has increased, the various reports on its safety for long-term treatment have also increased [6][7][8][9] . In Korea, there have been a few published studies on the efficacy of CsA treatment for patients with AD [10][11][12] .…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

The Efficacy and Safety of Long-term Oral Cyclosporine Treatment for Patients with Atopic Dermatitis

2010

View full text Add to dashboard Cite

Section: Discussioncontrasting

confidence: 51%

Section: Discussioncontrasting

confidence: 51%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

The Efficacy and Safety of Long-term Oral Cyclosporine Treatment for Patients with Atopic Dermatitis

2010

View full text Add to dashboard Cite

“…Classically, CsA has been used as an immunosuppressive agent in organ transplantation in humans and cats [2,3,12,36]. Recently, CsA has been reported as an effective drug for the long-term management of pruritus in human and canine atopic dermatitis (AD) [10,11,22,30]. In addition, several clinical trials have revealed that CsA is also effective for controlling pruritus in feline skin diseases [21,34].…”

mentioning

confidence: 99%

Cyclosporine A Inhibits Transcription of Cytokine Genes and Decreases The Frequencies of IL-2 Producing Cells in Feline Mononuclear Cells

2008

View full text Add to dashboard Cite

ABSTRACT. Cyclosporine A (CsA) has been widely used for suppression of transplant rejection and controlling pruritus in allergic dermatitis in humans, dogs and cats. CsA is known to suppress the expression of inflammatory cytokines, including IL-2, IL-4, IFN-γ and TNF-α in humans, dogs and experimental mice. However, little is known about the immunomodulating effect of CsA in cats. The aim of this study was to evaluate the effects of CsA on the expression of inflammatory cytokines in feline peripheral blood mononuclear cells (PBMC). Real-time PCR analyses with Concanavalin A (ConA)-stimulated PBMC obtained from 5 cats revealed that the expression of mRNAs for IL-2, IL-4, IFN-γ and TNF-α was inhibited by CsA in a dose-dependent manner. Moreover, an enzyme-linked immunospot (ELISPOT) assay, which is capable of detecting IL-2 secreting cells as single spots, revealed that the frequency of IL-2 secreting cells in ConA-stimulated feline PBMC was significantly reduced in the presence of CsA. These results might provide an explanation for the mechanisms of action of CsA in the suppression of transplant rejection and the control of pruritus in cats.

show abstract

Cyclic peptides as potential therapeutic agents for skin disorders

Namjoshi

Benson

2010

Biopolymers

View full text Add to dashboard Cite

There is an increasing understanding of the role of peptides in normal skin function and skin disease. With this knowledge, there is significant interest in the application of peptides as therapeutics in skin disease or as cosmeceuticals to enhance skin appearance. In particular, antimicrobial peptides and those involved in inflammatory processes provide options for the development of new therapeutic directions in chronic skin conditions such as psoriasis and dermatitis. To exploit their potential, it is essential that these peptides are delivered to their site of action in active form and in sufficient quantity to provide the desired effect. Many polymers permeate the skin poorly and are vulnerable to enzymatic degradation. Synthesis of cyclic peptide derivatives can substantially alter the physicochemical characteristics of the peptide with the potential to improve its skin permeation. In addition, cyclization can stabilize the peptide structure and thereby increase its stability. This review describes the role of cyclic peptides in the skin, examples of current cyclic peptide therapeutic products, and the potential for cyclic peptides as dermatological therapeutics and cosmeceuticals.

show abstract

Efficacy and safety of long‐term treatment with cyclosporin A for atopic dermatitis

Cited by 80 publications

References 16 publications

The Efficacy and Safety of Long-term Oral Cyclosporine Treatment for Patients with Atopic Dermatitis

The Efficacy and Safety of Long-term Oral Cyclosporine Treatment for Patients with Atopic Dermatitis

Cyclosporine A Inhibits Transcription of Cytokine Genes and Decreases The Frequencies of IL-2 Producing Cells in Feline Mononuclear Cells

Cyclic peptides as potential therapeutic agents for skin disorders

Contact Info

Product

Resources

About